Loading companies…
MT
Molecular Targeting Technologies, Inc.
United States · Biotech
A clinical-stage biotechnology company developing targeted radiopharmaceuticals for cancer treatment and diagnosis.
Keeping targeted radiopharmaceuticals in circulation
MTTI's EvaThera platform adds an Evans Blue derivative to tumor-targeting molecules. Its affinity for albumin is intended to extend circulation time and change how the radiopharmaceutical reaches tumor tissue.
Its investigational EBTATE combines an octreotate targeting peptide, an Evans Blue component and a chelator carrying lutetium-177. The company is also developing EBRGD for integrin-expressing cancers, including non-small cell lung cancer. MTTI is based in West Chester, Pennsylvania.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| National Cancer Institute R01 grant | $3.2M | National Cancer Institute — Participant |
Investors
National Cancer InstituteJoined National Cancer Institute R01 grantCoverage
Sep 22, 2026Molecular Targeting Technologies, Inc. · National Cancer Institute R01 grantSimilar companies
AnaCardioAnaCardio is a clinical-stage biopharmaceutical company developing medicines intended to improve heart muscle function in people with heart failure.€62.5M · Series B
AventixAventix builds sensor-based analytical instruments for laboratories. Its first product, Scarlett 01, measures liquid volumes across microplate wells without touching the sample, helping R&D teams check dispensing quality and catch volume variation before it affects assay results.€1.2M · Pre-seed
ATAptadir TherapeuticsRNA therapeutics designed to restore expression of silenced genes€40M · Seed